Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wharton-Jelly MSCs for Non-Healing Diabetic Foot Ulcer
NCT06231771Phase 2Not yet recruiting
- Sponsor
- SUPERGENICS LIFE SCIENCE SDN. BHD.
- Start
- May 2024
- Primary completion
- Oct 2024
- Modality
- Stem Cell Therapies
01
Overview
Phase 2, randomised, double-blind trial of Wharton-Jelly mesenchymal stem cells in diabetic foot ulcer (DFU) (2 arms), sponsored by SUPERGENICS LIFE SCIENCE SDN. BHD. Primary endpoint: Proportion of patients with complete healing/closure of the target ulcer at 6 weeks. Planned start May 2024; status: not yet recruiting.
02
Drugs
Wharton-Jelly mesenchymal stem cells
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT06231771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231771.